Shares of hVIVO plc (LON:HVO – Get Free Report) rose 10% on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares were traded during trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Trading Up 10.0 %
The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The company has a market cap of £144.58 million, a PE ratio of 708.33 and a beta of 0.97. The stock has a 50 day moving average price of GBX 20.36 and a 200 day moving average price of GBX 25.73.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- How to Effectively Use the MarketBeat Ratings Screener
- Sizing Up a New Opportunity for NVIDIA Investors
- How Technical Indicators Can Help You Find Oversold Stocks
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
